Neurodyn
Developer and incubator focused on identification, preclinical validation and development of natural bioactives and granulin-based therapeutic candidates for neurological diseases and brain health. Operates a wholly owned preclinical, neurological-disease focused CRO to generate in vitro and in vivo efficacy data, supports translational activities toward toxicology and IND submission, and licenses or spins out matured assets to commercial partners.
Industries
Nr. of Employees
small (1-50)
Products
Standardized brain-health oral formulation (ginsenoside-based with catechins and omega-3)
A standardized natural product formulation combining high-purity ginsenoside extract, green tea catechins and omega-3 fatty acids formulated with absorption-enhancement technology to increase brain bioavailability; clinically evaluated with fMRI in older adults.
Granulin/progranulin-based neuroprotective therapeutic candidates
Therapeutic candidates derived from progranulin and specific granulin combinations selected for neuroprotective activity and mitigation of TDP-43 and FUS proteinopathies across preclinical models of ALS, Parkinson’s disease and Alzheimer’s disease.
Standardized brain-health oral formulation (ginsenoside-based with catechins and omega-3)
A standardized natural product formulation combining high-purity ginsenoside extract, green tea catechins and omega-3 fatty acids formulated with absorption-enhancement technology to increase brain bioavailability; clinically evaluated with fMRI in older adults.
Granulin/progranulin-based neuroprotective therapeutic candidates
Therapeutic candidates derived from progranulin and specific granulin combinations selected for neuroprotective activity and mitigation of TDP-43 and FUS proteinopathies across preclinical models of ALS, Parkinson’s disease and Alzheimer’s disease.
Services
Contract research services focused on preclinical efficacy testing using in vitro assays and animal models for neurodegenerative disease programs.
Incubation of projects through preclinical and early clinical stages with options to license, partner or transfer assets to stand-alone entities and third-party marketers.
Contract research services focused on preclinical efficacy testing using in vitro assays and animal models for neurodegenerative disease programs.
Incubation of projects through preclinical and early clinical stages with options to license, partner or transfer assets to stand-alone entities and third-party marketers.
Expertise Areas
- Preclinical efficacy testing in neurological disease models
- Granulin/progranulin therapeutic discovery and development
- Natural product reformulation and brain-targeted supplements
- Transgenic and rodent models for neurodegeneration
Key Technologies
- Transgenic mouse models (TDP-43)
- In vitro motor neuron survival assays
- Microglial phenotype assays
- Formulation for enhanced brain bioavailability
News & Updates
Peer-reviewed publication describing progranulin expression in motor neurons and its role in promoting neuronal survival.
Publication reporting progranulin effects on zebrafish motoneuron development and rescue of truncation defects.
Study reporting protection of dopaminergic neurons by progranulin gene delivery in a Parkinson’s disease mouse model.
Publication describing neurotrophic effects of progranulin in models of TDP-43 or FUS dysregulation.
Study reporting reduced plaque burden and synaptic atrophy after progranulin gene delivery in an Alzheimer’s mouse model.
A galantamine prodrug asset was transferred to a spinout vehicle; the asset received regulatory approval for treatment of mild to moderate Alzheimer’s dementia (reported July 2024).
Peer-reviewed publication describing progranulin expression in motor neurons and its role in promoting neuronal survival.
Publication reporting progranulin effects on zebrafish motoneuron development and rescue of truncation defects.
Study reporting protection of dopaminergic neurons by progranulin gene delivery in a Parkinson’s disease mouse model.
Publication describing neurotrophic effects of progranulin in models of TDP-43 or FUS dysregulation.
Study reporting reduced plaque burden and synaptic atrophy after progranulin gene delivery in an Alzheimer’s mouse model.
A galantamine prodrug asset was transferred to a spinout vehicle; the asset received regulatory approval for treatment of mild to moderate Alzheimer’s dementia (reported July 2024).